Victory Capital Management
NAVB

Victory Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Victory Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,806
Closed -$4K – 3751
2020
Q1 		$4K Buy
+4,806
New +$5.3K ﹤0.01% 3611
2019
Q4 		– Sell
-2,849
Closed -$2K – 3775
2019
Q3 		$2K Buy
+2,849
New +$1.75K ﹤0.01% 3679

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
OFG
OTA Financial Group Purchase, New York $143M AUM 16.9% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Victory Capital Management's NAVB Position: Q2 2020 in Review

Victory Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2020, closing a stake of 4,806 shares — an estimated $4K sold.

Victory Capital Management first reported a position in NAVB in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2020. 41 funds tracked by Wall St. Rank hold NAVB as of Q2 2020.

  • Victory Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 4,806 Navidea Biopharmaceuticals Inc. shares in Q2 2020, an estimated $4K.
  • Victory Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $4K in Q1 2020.
  • 41 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.